Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trials

被引：0
|
作者：
Ciccarese, M. [1 ]
Bria, E. [1 ]
Cuppone, F. [1 ]
Nistico, C. [1 ]
Carlini, P. [1 ]
Natoli, G. [1 ]
Nuzzo, C. [1 ]
Terzoli, E. [1 ]
Cognetti, F. [1 ]
Giannarelli, D. [1 ]
机构：
[1] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI15 / XI15
页数：1
相关论文
共 50 条
  • [31] Disease-free survival as an end-point in the treatment of solid tumours - Perspectives from clinical trials and clinical practice
    Robinson, Andrew G.
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2298 - 2302
  • [32] Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials
    Li, Ling
    Pan, Zhanyu
    CLINICAL BREAST CANCER, 2018, 18 (01) : 63 - 70
  • [33] Overall Survival: Still the Gold Standard Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials
    Driscoll, James J.
    Rixe, Oliver
    CANCER JOURNAL, 2009, 15 (05): : 401 - 405
  • [34] Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials
    Loibl, Sibylle
    von Minckwitz, Gunter
    Harbeck, Nadia
    Janni, Wolfgang
    Elling, Dirk
    Kaufmann, Manfred
    Eggemann, Holm
    Nekljudova, Valentina
    Sommer, Harald
    Kiechle, Marion
    Kuemmel, Sherko
    BREAST CANCER RESEARCH, 2008, 10 (05)
  • [35] Reported Bone Pain in Patients with Breast Cancer Receiving Taxane-Based Chemotherapy in Clinical Trials of Pegfilgrastim
    Schwartzberg, L. S.
    Mo, M.
    Harms, R.
    Vogel, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 576S - 576S
  • [36] Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies
    Montagnani, Francesco
    Di Leonardo, Greta
    Pino, Maria Simona
    Martella, Francesca
    Perboni, Simona
    Ribecco, Angela
    Fioretto, Luisa
    ANTICANCER RESEARCH, 2016, 36 (08) : 4259 - 4265
  • [37] Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    Sargent, DJ
    Wieand, HS
    Haller, DG
    Gray, R
    Benedetti, JK
    Buyse, M
    Labianca, R
    Seitz, JF
    O'Callaghan, CJ
    Francini, G
    Grothey, A
    O'Connell, M
    Catalano, PJ
    Blanke, CD
    Kerr, D
    Green, E
    Wolmark, N
    Andre, T
    Goldberg, RM
    De Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8664 - 8670
  • [38] Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Pusztai, Lajos
    Broglio, Kristine
    Andre, Fabrice
    Symmans, W. Fraser
    Hess, Kenneth R.
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4679 - 4683
  • [39] Impact on overall survival and disease-free survival of adjuvant chemotherapy after neoadjuvant chemoradiotherapy for rectal cancer
    de Castro, Rafael Amaral
    Paiva, Carlos Eduardo
    Saad-Hossne, Rogerio
    Michelin, Odair Carlito
    Souza, Cristiano de Padua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara
    Junko Ikeda
    Tomoya Yokota
    Daisuke Takahari
    Takashi Ura
    Kei Muro
    Keitaro Matsuo
    Investigational New Drugs, 2012, 30 : 1224 - 1231
12345